| Current Price | $103.60 | Mkt Cap | $19.42B |
|---|---|---|---|
| Open | $0.00 | P/E Ratio | 26.50 |
| Prev. Close | $103.43 | Div. (Yield) | 0.40 (0.50%) |
| Daily Range | $103.34 - $104.16 | Volume | 1,092,606 |
| 52-Wk Range | $79.02 - $105.53 | Avg. Daily Vol. | 0 |
News & Discussion Boards
- Another Strong Year for Shire With Revenues Exceeding $4 Billion for the First Time and Non GAAP EPS up 26% to $5.34 2/9/2012 7:00:00 AM -
- Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD 2/7/2012 12:37:00 PM -
- Market Report -- In Play (SHPGY) 2/7/2012 12:18:00 PM -
- Vyvanse(R) (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD 2/7/2012 12:15:00 PM -
- Shire's Profits and Sales Beat Views, Forecasts Strong 2012 2/9/2012 9:48:00 AM
- Shire 4Q Pretax Profit $296.3M, Sees Good 2012 Earnings Growth 2/9/2012 7:38:59 AM
- Sangamo BioSciences To Partner With Shire To Develop DNA Technology 2/1/2012 8:34:00 AM
- Reasons To Stay Interested in SNWV - Analyst Blog 1/25/2012 12:37:01 PM
| Subject | Recs | Author | Date |
|---|



